ClinicalTrials.gg
RecruitingNCT06943053Wound coverageUpdated Apr 24, 2025

Evaluation of Ioband Coverage Waterproof Dressing Versus Isolated Waterproof Dressing After Primary Total Knee Arthroplasty

An interventional study of Isolate waterproof dressing (Opsite) and Ioban coverage group in Postoperative Wound Care After TKA, sponsored by Thammasat University Hospital. Recruiting at 2 sites in Thailand. Open to participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Thammasat University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

Title: Evaluation of Ioband® Coverage Waterproof Dressing in Post-Operative Total Knee Arthroplasty (TKA)

Goal: To evaluate the effectiveness of Ioband® coverage waterproof dressing compared to standard waterproof dressing in reducing dressing change frequency and peel-off degree post-op TKA.

Main Research Questions:

  1. Does Ioband® coverage waterproof dressing significantly decrease the degree of peel-off compared to standard waterproof dressing?
  2. Does Ioband® coverage reduce the number of wound dressing changes required post-operatively?
  3. Does Ioband® coverage improve overall patient satisfaction compared to standard waterproof dressing?

Participants:

Participants will include patients who have undergone total knee arthroplasty (TKA).

Main Tasks and Interventions:

  1. Randomization: Participants will be randomly assigned to receive either the Ioband® coverage waterproof dressing or the standard waterproof dressing.
  2. Application of Dressings: Participants will have the assigned dressing applied to their surgical site post-operatively.
  3. Assessment of Peel-Off Degree: Participants will undergo assessments to evaluate the degree of peel-off of the dressing over a specified time.
  4. Wound Dressing Changes: Participants will have their dressing changed as per routine care protocols, with documentation of the number of changes.
  5. Patient Satisfaction Survey: Participants will complete a satisfaction survey to assess their experiences with the dressing and overall comfort.

Conclusion: The trial aims to provide insights into the benefits of Ioband® coverage waterproof dressing in improving post-operative care for TKA patients, focusing on key outcomes related to dressing performance and patient satisfaction.

Read the detailed description

Study Design:

  • Participants: 96 patients undergoing TKA, randomly assigned to two groups of 48 each:
  • Intervention Group: Ioband® coverage waterproof dressing
  • Control Group: Standard waterproof dressing (Opsite®)

Randomization Method:

-Computerized block randomization performed by an independent research assistant.

Pre-operative Procedures:

  • Pre-emptive Analgesia administered 1 hour before surgery included:

    1. Naproxen (250 mg)
    2. Omeprazole (20 mg)
    3. Acetaminophen (500 mg)
    4. Pregabalin (75 mg)

      Anesthesia: Administered spinal anesthesia and ultrasound-guided adductor canal block by experienced anesthesiologists.

      Surgical Preparation:

  • Incision sites were prepped and draped using sterile technique.
  • Antiseptic Ioband® (60×45 cm) covered the incision site to prevent contamination.

Surgical Technique:

  • Utilization of a standard medial parapatellar approach with a minimally invasive TKA technique.
  • A tourniquet was inflated to 100 mmHg above systolic blood pressure and was deflated after wound closure.
  • Cemented posterior stabilizer prosthetics (Nexgen LPS) and patellar resurfacing were used.
  • Anesthetic cocktail (0.5% bupivacaine, adrenaline, ketorolac, morphine) was injected around the capsule after prosthesis insertion.

Post-operative Care:

  • No suction drains or extremity wraps used.
  • Wounds closed with waterproof dressing (Opsite® size 25×10 cm) in 90-degree knee flexion without tension.
  • Pain Management: Multimodal pain control was employed.
  • Antibiotic Prophylaxis: Administered for 24 hours post-surgery.
  • Rehabilitation: Early knee range of motion exercises and ambulation were encouraged within 24 hours post-operation.

Wound Management Protocol:

  • Patients were allowed to start bathing 48 hours post-op.
  • Dressing change on post-op day 3, using sterile technique:
  • Control Group: Covered with waterproof dressing (Opsite®).
  • Intervention Group: Covered with Ioband® in knee flexion.

Wound Care Instructions:

  • Keep covering material dry and clean; avoid irritation.
  • Report any signs of infection (redness, swelling, fever) to a doctor.
  • Avoid creams or powders unless prescribed.
  • Avoid scratching or rubbing around the wound.
  • Light activities permitted; avoid strenuous activities for 6 weeks.
  • Dressing should not be changed until advised, typically after 14 days unless signs of complications are observed.

Criteria for Dressing Change:

  • Change dressing if:
  • First waterproof dressing peels off grade II or III.
  • Second dressing has over 50% bleeding.
  • Suspected surgical site infection. Patients were also included in a chat group for wound care consultation.
02

Conditions studied

  • Postoperative Wound Care After TKA

Keywords

  • total knee arthroplasty
  • Ioband® coverage waterproof dressing
03

In context

Lead sponsor

Thammasat University Hospital is the lead sponsor of 16 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary unilateral TKA
  • Age 55-80 yrs

Exclusion criteria

Exclusion Criteria:

  • Chronic Skin disease such as Psoriasis
  • Chronic use
  • Allergy to skin adhesive, Cover wound
  • Robotic TKA
  • Iodine allergy
  • Not follow protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Active comparator
    Control Group: Isolated waterproof dressing (Opsite®).

    Isolated waterproof dressing (Opsite®).

    Device: Isolate waterproof dressing (Opsite)

  • Experimental
    Ioban Coverage group

    Participants in this group will receive an Ioban iodine-impregnated antimicrobial incise drape placed over the standard water proof dressing at the end of primary total knee arthroplasty.the ioban drape extends 2 cm beyond the edge of the primary dressing and remain in place until dressing remove

    Device: Ioban coverage group

Interventions

  • DeviceIsolate waterproof dressing (Opsite)

    Application of standard Opsite® waterproof dressing directly over the surgical incision following primary total knee arthroplasty. No additional drape or coverage was applied. The dressing remained in place until removal.

  • DeviceIoban coverage group

    Application of Ioban® iodine-impregnated antimicrobial incise drape over the standard waterproof dressing following primary total knee arthroplasty. The Ioban drape extends 2 cm beyond all edges of the dressing and remains in place until removal.

06

What researchers measure

Primary outcomes

  1. Number of change wound dressing

    Indication for changing wound dressing before appointment 1. Post op wound with waterproof peel off grade II (waterproof peel off to pad) or grade III (waterproof peel off involve into pad) 2. Waterproof has bloody more than 50 % 3. suspected Surgical site infection

    Time frame: 14 days postoperation

Secondary outcomes

  1. Degree of peel off wound

    There are 4 types of Characteristics of the Wound Sealant Leakage Level 0: No leakage of the plastic sealant. No need to open the wound Level 1: Plastic sealant leaks around the edges but not into the wound. No need to open the wound Level 2: Plastic sealant leaks around the edges up to the wound edge. Open the wound and re-seal with a new sealant Level 3: Plastic sealant leaks deep into the wound edges. Open the wound and re-seal with a new sealant

    Time frame: 14 days postoperation

  2. Satisfactory of patient

    * Satisfactory of patient: (score1-10) * Comfort for wound care (score 0-10) * Difficult to take a bath (score 0-10) * Pain on remove dressing (score 0-10) * Cost for Dressing after D/C

    Time frame: 14 days post-operation

  3. Post op Range of motion of knee

    Degree of flexion

    Time frame: At 2 weeks, 6 weeks and 3 months postoperation

  4. Wound-related Complication

    Wound-related Complication * Skin bleb, redness * Dehiscence * Subcutaneous hematoma * Surgical site infection

    Time frame: At 2 weeks, 6 weeks and 3 months postoperation

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • 1 Primary Total Knee Replacement: A Recipe for Dry Dressing Azfar KM, Adil AO, Tarig AR, Adel G. Primary Total Knee Replacement: A Recipe for Dry Dressing. Cureus. 2023;15(4). 2 The effect of different wound dressing materials used in postoperative treatment of wounds after total hip arthroplasty and total knee arthroplasty: A meta-analysis Yingjia Yuan, Jin Li, Ke Wang, Guanqiang Zheng, Shengting Chai. The effect of different wound dressing materials used in postoperative treatment of wounds after total hip arthroplasty and total knee arthroplasty: A meta-analysis.IWJ. : April 2022. 3 Clinical outcome of different skin closure in TKA Chen L, Yang J, Xie J, Hu Y, Zeng M. Clinical outcome of different skin closure in total-knee arthroplasty: running subcuticular closure vs intermittent closure: a retrospective study. Medicine. 2020 Aug 8;99(34). 4 Closure in knee replacement surgery Kharat K. Closure in knee replacement surgery. Journal of Orthopaedic Case Reports. 2012 Jul;2(3):31. 5 Multilayer watertight closure to address adverse event from primary total knee and hip arthroplasty Snyder MA, Chen BP, Hogan A, Wright GW. Multilayer watertight closure to address adverse events from primary total knee and hip arthroplasty: a systematic review of wound closure methods by tissue layer. Arthroplasty today. 2021 Aug 1;10:180-9. 6 Persistent wound drainage after total joint arthroplasty: a narrative review Wagenaar FC, Löwik CA, Zahar A, Jutte PC, Gehrke T, Parvizi J. Persistent wound drainage after total joint arthroplasty: a narrative review. The Journal of Arthroplasty. 2019 Jan 1;34(1):175-82. 7 Effect of the knee position during wound closure after TKA on early knee function recovery. Wang S, Xia J, Wei Y, Wu J, Huang G. Effect of the knee position during wound closure after total knee arthroplasty on early knee function recovery. Journal of Orthopaedic Surgery and Research. 2014 Dec;9(1):1-6

Individual participant data

Plan to share: No — The datasets analyzed during the current study are not available due to protect study participant privacy.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Apr 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 24, 2025
StartActual
Apr 6, 2025
Primary completionEst.
Apr 6, 2026
CompletionEst.
Apr 16, 2026
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06943053
Lead sponsor
Thammasat University Hospital
Responsible party
Yot Tanariyakul (Krit Boontanapibul, Thammasat University Hospital) — Principal investigator
First posted
Apr 24, 2025
Start date
Apr 6, 2025
Primary completion
Apr 6, 2026 (estimated)
Completion
Apr 16, 2026 (estimated)
Last update
Apr 24, 2025

Study contacts

Krit Boontanapibul, M.D.
Contact
krit.boontanapibul@gmail.com
66613957799
Chanon Thassanaleelaporn, M.D.
Contact
C.pond21@gmail.com
Chanon Thassanaleelaporn, M.D.
principal investigator · Thammasat University Hospital Thailand
Krit Boontanapibul, M.D.
study director · Thammasat University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion